39160-70-8

Usage

Uses

Used in Pharmaceutical Industry:
H2N-PEG6-OH is used as a PEGylation agent for improving the solubility, stability, and bioavailability of therapeutic proteins and drugs. The hydrophilic PEG spacer reduces the immunogenicity and proteolytic degradation of the conjugated molecules, thus extending their circulation time in the body.
Used in Diagnostics:
H2N-PEG6-OH is used as a key component in the preparation of single-cell optical biosensors. The hydrophilic PEG spacer and reactive amine group facilitate the attachment of specific recognition elements, such as antibodies or other binding molecules, to the sensor surface, enabling the detection and analysis of target analytes at the single-cell level.
Used in Drug Delivery Systems:
H2N-PEG6-OH is used as a building block for the development of novel drug delivery systems, such as nanoparticles and micelles. The PEG spacer improves the solubility and biocompatibility of these systems, while the reactive amine group allows for the conjugation of therapeutic agents, targeting moieties, or imaging agents to enhance their specificity and efficacy.
Used in Bioconjugation and Chemical Synthesis:
H2N-PEG6-OH is used as an intermediate in the synthesis of various bioconjugates, such as PEGylated proteins, peptides, and small molecules. The reactive amine group can be used to form stable amide or urea linkages with carboxylic acid-containing compounds, enabling the creation of diverse PEGylated products with tailored properties and applications.

Upstream product

• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 86770-73-2 {2-[2-(2-{2-[2-(2-Azido-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxymethyl}-benzene 
• 141282-27-1 2-(17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl)isoindoline-1,3-dione 
• 2615-15-8 pentaethylene glycol 
• 352439-34-0 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl methanesulfonate 
• 42749-28-0 toluene-4-sulfonic acid 2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl ester 
• 37860-51-8 tetraethylene glycol di(p-toluenesulfonate) 
• 112-60-7 Tetraethylene glycol 
• 669556-37-0 17-(tetrahydro-2H-pyran-2-yloxy)-3,6,9,12,15-pentaoxaheptadecyl 4-methylbenzenesulfonate 
• 24342-68-5 1-phenyl-2,5,8,11,14,17-hexaoxanonadecan-19-ol 
• 1663-39-4 tert-Butyl acrylate 
• 127999-16-0 19-(triphenylmethyl)-1,4,7,10,13,16,19-heptaoxanonadecanol 
• 745048-16-2 19,19,19-triphenyl-3,6,9,12,15,18-hexaoxanonadec-1-ylmethanesulfonate 
• 1444123-36-7 C₃₁H₃₉N₃O₆ 

Downstream Products

• 250330-58-6 benzyl N-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate 
• 1219133-47-7 C₄₈H₈₉NO₁₀ 
• 1219133-43-3 C₆₁H₁₁₅NO₁₀ 
• 911209-07-9 tert-butyl N-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate 
• 189209-27-6 tert-butyl N-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy] ethoxy]ethoxy]ethyl]carbamate 
• 391684-36-9 2-(2-(2-(2-(2-(2-t-butyloxycarbonylaminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxyacetatic acid 
• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 1426687-08-2 tert-butyl (17-(((4S)-6-(4-chlorophenyl)-4-(2-(ethylamino)-2-oxoethyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-8-yl)oxy)-3,6,9,12,15-pentaoxaheptadecyl)carbamate 

Relevant academic research and scientific papers

Development of chemically stable solid phases for the target isolation with reduced nonspecific binding proteins

Poly(methacrylate) matrices for affinity resins were designed and synthesized based on our previous results that nonspecific protein absorption on affinity resins strongly depended on their hydrophobic property. The novel affinity resins bearing FK506 (6a, 6b) captured specific binding protein, FKBP12, with a small amount of nonspecific binding proteins. The amount of nonspecific binding proteins on 6a-6b was much reduced compared to that on commercially available poly(methacrylate) resins, Toyopearl (8), and was almost the same as that on one of the most popular resins, Affigel (9). Interestingly, 6a and 6b could isolate FKBP52 as a specific binding protein as well, although 8 and 9 could not.

Aromatically functionalized pseudo-crown ethers with unusual solvent response and enhanced binding properties

Conformational flexibility in the host's structure is often considered detrimental to its binding. Flexible pseudo-crown ethers with aromatic donor/acceptor groups at the chain ends, however, displayed enhanced binding affinity and selectivity, particularly when the direct binding interactions were compromised by unfavorable solvents.

Self-adhesion among phospholipid vesicles

A compound was synthesized that binds to a phospholipid bilayer via a hydrophobic steroid thereby projecting a strong multi-hydrogen bonding unit into the surrounding water. As shown by light scattering, light microscopy, and cryo-HRSEM, this latter unit self-adheres and induces membrane-membrane attachments, as found in many biological systems. Copyright

THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE

The present application is directed to a therapeutic composition, comprising two precursor compounds (monomers) that are suitable for assembly via two or more reversible covalent bonds. The monomers are polyfunctionalized molecules comprising a bioorthogo

THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM

The present application is directed to a therapeutically useful compound, comprised of two monomers that are linked to each other through two or more reversible covalent bonds. Each monomer is a polyfunctionalized molecule comprising a bioorthogonal linker element and ligand or pharmacophore, wherein the linker and ligand/pharmacophore are covalently coupled to each other either directly or through an optional connector moiety.

Supramolecular compound nano-carrier as well as preparation method and application thereof

The invention discloses a supramolecular compound nano-carrier as well as a preparation method and application thereof, and relates to the technical field of polymer chemistry and biological detection engineering. According to the supramolecular compound nano-carrier disclosed by the invention, a two-dimensional nanosheet supramolecular structure system generated by self-assembly is driven by an anion induction effect, and a supramolecular compound nano-carrier is of a single-layer nanosheet supramolecular structure constructed by a highly-oriented one-dimensional nanorod. A hydrophobic perylene group part is used as a skeleton part for constructing the highly-oriented one-dimensional nanorod, and the charge density of a single-layer nanosheet can be regulated and controlled. The surface of the water-soluble multivalent hydrophilic part can be loaded with DNAzyme deoxyribozyme for specific detection of heavy metal ions through electrostatic interaction, and the water-soluble multivalent supramolecular compound nano sensor is constructed. Based on a fluorescence change mechanism caused by specific cutting of heavy metal ions, The fluorescence detection of the heavy metal ions in food and biological tissues is realized, and the detection effect of the heavy metal ions is greatly enhanced.

PROTAC compound for targeted degradation of IDO1, and preparation method and application thereof

The invention provides a PROTAC compound represented by formula I and used for targeted degradation of IDO1, and a pharmaceutically acceptable salt, a hydrate or a solvate thereof. In the formula I, Xrepresents -CH2 or -C = O, Y represents -CH2 or -C= O, and n is a natural number from 2 to 9. The PROTAC compound for targeted degradation of the IDO1 has efficient activity of targeted degradation of the IDO1 protein.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

EXENATIDE MODIFIER AND USE THEREOF

Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.